Saturday 17 October 2026
Export AVTR’s income statement to Excel — free account
Avantor, Inc.
AVTR Healthcare Medical Instruments & Supplies
Avantor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 billion, down 3.41% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 33.3%, free cash flow grew 12.7% and total debt fell 12.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
16.42
0.33
+2.05%
Follow AVTR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.29 | 1.19 | 0.81 | 1.02 | |
P/FCF ratio |
16.25 | 15.76 | 12.07 | 14.72 | |
P/Operating CF |
41.02 | 51.08 | 90.25 | 37.57 | |
P/B ratio |
1.53 | 1.40 | 0.95 | 1.19 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.84 | 1.74 | 1.35 | 1.54 | |
EV/EBITDA |
17.75 | 65.97 | 68.22 | 80.81 | |
EV/Operating CF |
18.80 | 18.24 | 15.41 | 16.89 | |
EV/FCF |
23.14 | 22.99 | 20.13 | 22.18 | |
Quick Ratio |
0.88 | 1.04 | 1.01 | 1.05 | |
Current Ratio |
1.49 | 1.78 | 1.76 | 1.78 | |
Net Debt/EBITDA |
(6.65) | 15.46 | 17.14 | 14.80 | |
Debt/Assets |
33.04% | 33.46% | 32.72% | 31.89% | |
Debt/Equity |
0.69 | 0.71 | 0.68 | 0.66 | |
Asset Turnover |
0.54 | 0.55 | 0.55 | 0.54 | |
Operating CF/Net income |
(0.29) | 2.91 | 1.36 | 4.68 | |
Capex/Depreciation |
(0.33) | (0.34) | (0.31) | (0.35) | |
Interest Coverage |
(14.68) | 3.16 | 2.32 | 3.09 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
24.04% | 23.59% | 25.37% | 24.53% | |
Intangible Assets out of Total Assets |
0.71 | 0.69 | 0.69 | 0.69 | |
Share Based Compensation of Revenue |
0.44% | 0.68% | 0.54% | 0.91% | |
Graham Net Nets |
(0.45) | (0.48) | (0.69) | (0.52) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.96%) | (6.81%) | (10.33%) | (8.48%) | |
Free Cash Flow Yield |
6.15% | 6.35% | 8.29% | 6.79% | |
Revenue per Share |
2.38 | 2.44 | 2.34 | 2.50 | |
Operating CF per Share |
0.30 | 0.22 | 0.09 | 0.26 | |
Capex per Share |
(0.05) | (0.05) | (0.05) | (0.06) | |
Free Cash Flow per Share |
0.25 | 0.17 | 0.04 | 0.21 | |
Cash per Share |
0.37 | 0.54 | 0.41 | 0.45 | |
Shareholders Equity per Share |
8.17 | 8.18 | 8.27 | 8.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.17 | 8.18 | 8.27 | 8.33 | |
Free Cash Flow |
171.70 | 117.20 | 25.20 | 140.60 | |
Working Capital |
740.70 | 1,072.30 | 1,037.00 | 1,080.20 | |
Capital Expenditures |
(35.70) | (35.50) | (33.50) | (37.60) | |
Net Current Asset Value |
(3,848.50) | (3,778.50) | (3,670.00) | (3,503.50) | |
EV/EBIT |
45.63 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
32.04 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1,082.70 | 1,054.55 | 1,100.55 | 1,144.15 | |
Average Payables |
682.55 | 702.25 | 707.80 | 726.00 | |
Average Inventory |
787.55 | 774.85 | 780.20 | 804.25 | |
Average Assets |
12,258.25 | 11,954.60 | 11,994.70 | 12,186.40 | |
Average Common Equity |
5,561.70 | 5,760.85 | 5,843.45 | 5,958.05 |
Columns are period end dates